The ACR’s director of regulatory affairs, Amanda Grimm Wiegrefe, MScHSRA, can be reached at [email protected].
Related Articles
Rheumatology in a COVID & Post-COVID World
Jane’s* hands and wrists had been swollen and painful for about eight weeks. Lab findings in the ambulatory consult that came to our office revealed a cyclic citrullinated peptide antibody count >250 u/mL. We all know where this story goes, including how important the early treatment window is. Our clinic reviews all consults and tries…
What’s Next for Telehealth after the COVID-19 Public Health Emergency?
Do you remember where you were when the COVID-19 Public Health Emergency (PHE) was declared on Jan. 31, 2020? While it may seem like yesterday, you would be forgiven for not recalling your exact location over three years ago during what felt like an incredible whirlwind for the healthcare industry. One possible location you may…
Reimbursement Tips: Telemedicine & Coding in the Time of COVID-19
Humans may fear change as a general rule, but we’re adaptable when we need to be. In this era of COVID-19 and social distancing, medical practices and payers are adapting to an increased use of telemedicine, which enables providers to see their patients without being in a room with them. To cope, the Centers for…
Telerheumatology: What’s Next?
In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.